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ANNEXURE 
MASTER CHART 
 
   
INTRODUCTION 
 
 Nervous system neoplasms are common neoplasm affecting both 
adults and children. The effects of these tumours were devastating 
even though they constitute a small percentage of all cancers
(1)
 
 Incidence, prevalence and survival rates are important to know the 
burden of disease among different populations. Over all incidence 
varies between 9.21 to 18.1 per 100,000 person years in various 
studies.
(2,6,7)
 Variation in these rates prompted us to find out 
aetiology, treatment and prognosis of the disease 
(2)
. 
 As most of the studies done on nervous system tumours were 
institutional they were prone for bias due to inclusion and 
exclusion of cases. 
 In developed countries like United States, central brain tumour 
registry of United States (CBTRUS) maintains the brain tumour 
data from various cancer registries. But in developing countries 
like India, due to complete lack of registration of newly diagnosed 
cases, with local registry the exact burden of these tumours goes 
unnoticed and is under estimated. In these settings multi 
institutional tertiary care hospital data forms the basis for 
estimating the disease load. 
 There is dire need for descriptive data on primary brain and 
nervous system tumours as highlighted by Kurland and 
Schoenberg
(3)
. Hence this study is contemplated with a view to get 
descriptive data. 
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 In contrast to western literature there is no report exclusively 
available for brain tumours in India. 
 Among tumours of the nervous system, those with papillary 
configuration constitute the vast majority and produces difficulty in 
diagnosis. Papillary neoplasms of nervous system include both 
primary central nervous system and spinal cord tumours as well as 
metastatic papillary tumours. 
 Often the histological appearance alone cannot conclude the 
diagnosis. In difficult cases use of immunohistochemistry aid in 
differentiating metastasis from primary tumour, histological sub 
typing and grading. These are needed for the proper treatment and 
prognostic assessment. 
 In this study we analysed the data from our tertiary care hospital to 
find the epidemiology of papillary neoplasms of nervous system, 
histopathology, and employed immunohistochemistry to 
differentiate each tumour. 
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AIMS AND OBJECTIVES 
 
1. To study the incidence of papillary neoplasms of nervous system. 
2. To study the histopathological features with relevance to 
histological behaviour and grading of papillary tumours. 
3. To study the role of immunohistochemistry in their differential 
diagnosis and classification. 
4. To study the immunohistochemical expression in primary nervous 
system tumours. 
5. To study the possible primary sites in nervous system metastatic 
tumours 
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REVIEW OF LITERATURE 
Papillary neoplasms are a heterogeneous group of neoplasms 
composed of papillary arrangement of cells with central fibro vascular 
core. These include both primary and secondary papillary neoplasms.  
Primary tumours constitute both glial and non glial origin with variable 
tumour grades. 
These tumours include 
Primary tumours: 
1. Myxopapillary ependymoma 
2. Papillary ependymoma 
3. Choroid plexus papilloma 
4. Atypical choroid plexus papilloma 
5. Choroid plexus carcinoma 
6. Papillary craniopharyngioma 
7. Papillary meningioma 
8. Papillary tumour of pineal region 
9. Papillary glio neural tumour 
10. Astroblastoma 
11. Ependymoblastoma 
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Metastatic tumours: 
1. Lung carcinoma 
2. Gastro intestinal carcinoma 
3. Renal cell carcinoma 
4. Ovarian carcinoma 
5. Uterine carcinoma 
6. Thyroid carcinoma 
 Epidemiological analysis, histopathological study and grading of 
these tumours are important for better treatment planning and to assess 
the prognosis. 
* EPIDEMIOLOGY OF NERVOUS SYSTEM TUMOURS: 
* T.S Surawicz et al 
(4)
 analysed 20765 central nervous system 
tumours obtained from CBTRUS during the year of 1990-1994 and 
concluded that average primary brain tumour incidence was 11.5 
per 100,000 person-years. In this study male patients have higher 
incidence (12.1 per 100,000 person-years) than female patients (11 
per 100,000 person-years) which was statistically significant. This 
study showed whites had higher incidence (11.6 per 100,000 
person-years) than blacks (7.8 per 100,000 person-years). 
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* Faith et al 
(2)
 studied the data from Surveillance, Epidemiology and 
End Result Program (SEER) and CBTRUS during 1973-1999 and 
highlighted the increase in incidence of brain tumour. In this study 
they compared the previous study done by Kurland et al., 
Schoenberg et al., and found out that under reporting and 
definitional differences were the causes for under ascertainment in 
these studies.  
* Analysis of 54,336 primary central nervous system tumours were 
done by Arora et al
(6) 
They studied central nervous system tumour 
epidemiology in England during the period of 1995-2003 and  
showed an overall incidence of 9.21 per 100,000 person-years with 
higher incidence in males (9.96 per 100,000 person-years) than 
females (8.52 per 100,000 person-years) with a male : female ratio 
of 1.17:1. 
* Porter et al 
(7)
 studied brain tumour prevalence in United States and 
found an overall incidence rate of 18.1 per 100,000 person-years 
for primary brain tumours. 
* T.S Surawicz et al 
(4)
 showed that meningiomas (24.0%) were the 
most frequently reported. In this study except meningioma all other 
nervous system tumours had male predominance and showed an 
6
annual incidence of 7.8 per 100,000 person-years for malignant 
tumours and 2.1-8.9 per 100,000 person-years for benign tumours. 
* Arora et al 
(6)
 showed a peak incidence of primary brain tumours in 
males and females of 75-79 years age group. Patients in the age 
group of 0-14 years had incidence of 3.56 per 100,000 person-
years, those in 15-24years age group had 3.47 per 100,000 person –
years incidence, and those in 25-84 years age group had 14.57 per 
100,000 person-years incidence. 
* Hoffman et al 
(5)
 studied 25,258 primary and other central nervous 
system tumours and documented an increased incidence of all brain 
tumours with a 1.1% increase over the average annual percentage 
which was statistically significant. In this study the majority of 
tumour (53%) occurred in 20-64 year age group; 38% occurred in 
the elderly (≥65 years) and 9% of the tumour occurred in children. 
* Arora et al 
(6)
 studied the brain tumour behaviour and showed 60% 
incidence for malignant tumour, 5.64% for benign tumour and 0.79 
– 2.78 for uncertain behaviour. Distribution by site showed that 
supratentorial and meningeal tumours affect older age group and 
infra tentorial tumours affect younger patients. Histologically 
neuro epithelial tumours affect younger patients and unspecified 
tumours affect older age. 
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* Data from SEER program and national cancer registry revealed 
nervous system tumours constitute about 27% of paediatric 
tumours 
(8)
. 
* Linabery et al
(9)
, studied the childhood cancer incidence from 
national cancer institute data during the period of 1992-2004. In 
this study over all childhood cancer incidence was 158 per 
1,000,000 person-years. CNS tumours constitute 27 per 1,000,000 
person-years. Male children had higher incidence (29.9 per 
1,000,000 person-years) than female children (25.1 per 1,000,000 
person-years). Age wise children less than 1 year had an incidence 
of 30.3 per 1,000,000 person-years. Children between 1-4 years 
and 5-9 years had an incidence 38.5 and 29.7 respectively. 
Children between 10-14 years had 25.2 per 1,000,000 person-years 
incidence. Children between 15-19 years had incidence of 19 per 
1,000,000 person-years. Compared to blacks (22.1%) whites had 
higher incidence (29%). Asian children had an incidence of 20.5 
per 1,000,000 person-years. 
* A multi institutional study by Jain et al 
(10)
 in India showed that 
paediatric CNS tumours constituted about 14.8% of intra cranial 
tumours. Among them astrocytomas were the most common 
tumours. 
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 EPIDEMIOLOGY OF NERVOUS SYSTEM METASTASIS: 
* Barnholtz et al 
(11)
 studied the incidence of brain metastasis during the 
period of 1973-2001 from the Metropolitan Detroit Cancer 
Surveillance System and revealed that the percentage of metastases 
was 9.6%. Among this lung (19.9%) was the most common site for 
primary, followed by melanoma (6.9%), renal (6.5%), breast (5.1%), 
and colorectal (1.8%) cancers. The highest incidence proportion %( 
IP) of brain metastasis occurred at different ages at diagnoses:  40 to 
49 years for primary lung cancer; 50- 59 years for primary melanoma, 
renal, or colorectal cancers; 20 to 39 years for primary breast cancer. 
Incidence proportion % was significantly increased as Surveillance, 
Epidemiology and End Result Program stage of primary cancer 
advanced for all primary sites. 
 
* Smedby et al 
(12)
, studied brain metastasis in Sweden between 1987 
and 2006 and concluded that the annual age-adjusted incidence rate of 
hospitalisation for brain metastasis  doubled from 7 to 14 patients per 
100 000 between 1987 and 2006. The most common primary tumours 
among women were lung (33%), breast (33%) and colorectal cancer 
(7%), and among men lung cancer (44%), malignant melanoma (12%) 
and colorectal cancer (9%). The increase was most evident for brain 
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metastasis patients with lung cancer (both sexes) and breast cancer 
(women). 
 
* EPIDEMIOLOGY OF PAPILLARY NEOPLASM OF 
NERVOUS SYSTEM: 
 Even though papillary neoplasms constitute a small percentage in 
nervous system tumours the descriptive epidemiology is needed for the 
diagnosis, treatment and assessing the prognosis. 
Primary papillary neoplasms: 
* Myxopapillary ependymoma: 
* The frequency of myxopapillary variant is 9–13 %( 13, 14) 
among all ependymomas. These tumours constitute the most 
common intramedullary neoplasm. The conus medullaris/ 
cauda equina region shows an incidence of 0.08 in males and 
0.05 per 100 000 persons per year in females
 (15)
. They occur 
in a wide range of age groups between 6-82 years 
(16)
. 
* Cervoni et al 
(17)
 studied 320 filum terminale ependymomas. 
In this 83% were of myxopapillary type, with a male: female 
ratio 2.2:1. 
* Papillary ependymoma  
* Based on Central Brain Tumour Registry of the United 
States (2006) ependymomas have 0.22-0.29 per 100,000 
10
person-years incidence
(15)
. This incidence is mainly affected 
by location and histological type. As per WHO the incidence 
of papillary ependymoma statistics was not available. 
 
* Choroid plexus tumours: 
* Choroid plexus tumours consist of choroid plexus papilloma, 
atypical choroid plexus papilloma, and choroid plexus 
carcinoma. Among all brain tumours these tumours 
constitute about 0.3-0.6%. However they represent 2-4% of 
nervous system tumours in children <15 years, and 10-20 % 
in those occurring in 1
st
 year of life.  
* As per Janisch et al, Rickert et al, and Wolff et al the 
approximate annual incidence of these tumours was 0.3 per 
1,000,000 populations per year.
(18,19,20)
. Male: female ratio 
was1.2:1. Approximately 80% of lateral ventricular tumours 
occur in less than 20 years age group, whereas 4
th
 ventricle 
tumours were equally distributed in all age groups. 
* As per Janisch W et al, Strojan P et al
 (18,21) 
 study most 
common site for CPP and CPC was lateral ventricle (50%) 
followed by third ventricle (5%), and fourth ventricle (40%). 
 
* Papillary craniopharyngioma: 
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* As per Bunin GR et al, 
(22)
 craniopharyngioma constitute 1.2-
4.6% of all intracranial tumours. They account for 0.5-2.5 
new cases per 1,000,000 population per year and 5-10% 0f 
intracranial tumours in children.
(23)
 In children these tumour 
were the most common non-neuroepithelial intracerebral 
neoplasms. 
* Papillary craniopharyngioma 
(23, 24) 
occurs exclusively in 
adults with a mean age of 40-45 years with no sex 
predilection. Suprasellar is the most common site. Koral et 
al, noted unusual locations like sphenoid sinus.
(25) 
 
* Papillary meningioma: 
* As per Claus et al
 (26)
 24-30% of  intracranial tumours were 
meningiomas in USA and average annual incidence ranged 
up to 13 per 100,000 population in Italy. Middle aged and 
elderly people were the most commonly affected people with 
peak during the 6
th
 and 7
th
 decades. 
(27)
 Middle aged females 
showed a higher incidence with female: male ratio 1.7:1.  
Jasskelainen et al
(28)
 analysed and found a male 
predominance in atypical and anaplastic meningiomas. As 
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per WHO the exact frequency of papillary meningioma was 
not available because of its rarity. 
 
* Papillary tumour of pineal region (PTPR): 
* In the pineal region it is a rare neoplasm of adults. Jouvet et 
al
(76)
 studied a series of 6 cases with similar histology and 
described PTPR in 2003. Since these tumours were rare, 
incidence data were not available. In this sex predilection 
was not noted and the age group was 5-66 years with mean 
age of 32 years. 
 
* Papillary glioneuronal tumour: 
* Komori et al, 
(29)
 described this different clinicopathologic 
entity in 1998. As per WHO, population based 
epidemiological data was not available for this tumour. Only 
several case reports were available for this tumour.
(30,31)
 
These tumours have a wide age range and they do not have 
gender predilection 
. 
* Other uncommon papillary tumours: 
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* Astroblastoma a rare glial tumour mostly affecting children, 
young adults, and adolescents. These are very unusual 
neoplasm and no uniform criteria applicable for diagnostic 
purpose. So no definitive epidemiological data available 
(32)
. 
As per WHO 40 cases in three series analysed and found that 
median age was 11 years with range of 1-58 years. Among 
these all affected patients were females, suggesting a female 
preponderance. 
* Medulloepithelioma a malignant embryonal rare brain 
tumour occurring in young children between 6 months-5 
years with 50% cases affecting first two years
(33)
. Age at 
presentation ranged from <1 month – 23 years in 37 
published cases with equal male: female ratio. 
(33,34,35,36) 
 
* Metastatic papillary tumours of nervous system:  
* In nervous system tumours metastatic tumours were the most 
common tumours with up to 11 per 100,000 population per 
year probably under diagnosed and underestimating the true 
incidence
(37)
. 
* Gavrilovic et al
(38)
 autopsy study revealed that 25% of 
patients who die of cancer had brain metastases. 
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* As per Stone et al and Donadey et al 
(39,40)
 4-15% patients 
with solid cancer had leptomeningeal metastasis and 8-9% of 
patients had leptomeningeal and dural metastasis 
respectively. 
* Mut et al
(41)
 studied spinal and intramedullary metastasis and 
concluded that 5-10% of all patients with cancer had 
frequent spinal and intramedullary metastasis. 
* As per Suki et al,
(37)
 <25 years age group people have <1 per 
100,000 incidence, and greater than 30 per 100,000 at age of 
60 years. 
* Khan et al study
(42)
 showed that brain metastasis occur in 
30% of adults and 6-10 % of children with cancer. 
* Most common metastasis with papillary pattern are  
 Lung carcinoma 
 GIT malignancy 
 Breast carcinoma 
 Papillary carcinoma thyroid 
 Papillary renal cell carcinoma 
 Female Genital Tract carcinoma with papillary 
architecture 
 Male genito urinary tract malignancy 
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 Head and Neck malignancy 
HISTO MORPHOLOGY OF PAPILLARY TUMOUS: 
 Primary papillary tumours: 
 Myxopapillary ependymomas are WHO GRADE 1 tumour. 
Grossly these are encapsulated, lobulated and soft in 
consistency and greyish in colour. 
 Histologically these tumours are composed of cuboidal to 
columnar cells arranged in a papillary manner around the 
vascular core. In between the blood vessels and tumour cells, 
abundant myxoid material accumulates which shows alcian 
blue positivity. 
 Papillary ependymomas are WHO grade II tumours. Grossly 
they appear soft tan tumours with well demarcated borders. 
In histology they are formed by single layer of cuboidal 
tumour cells forming papillae. Perivascular arrangement is 
also seen. These cuboidal tumour cells show smooth 
contiguous surface.
(43)
 
 Choroid plexus papillomas (WHO grade I tumour) are 
circumscribed and cauliflower like masses which is usually 
well demarcated from the adjacent brain tissue. 
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Histologically they have papillary pattern with central 
delicate fibro vascular core. These cores are lined by 
uniform single layer of cuboidal to columnar cells. Cells 
have oval to round, basally situated uniform nuclei. They 
have very low mitotic activity. 
 Aquiline et al, Buccoliero et al, Sarkar et al (44,45,46) studied 
choroid plexus papilloma and found out unusual histologies 
including mucinous degeneration, oncocytic change and 
melanisation, as well as degenerative change including  
xanthomatous degeneration, cartilage, bone and adipose 
tissue formation. 
 Atypical choroid plexus papilloma (WHO grade II) is 
defined as choroid plexus papilloma with increased mitotic 
activity. 
 Jeibmann et al(47) study showed that a mitotic index of 2 or 
more per 10 randomly selected high power fields can be 
used to diagnose atypical CPP. This  study also established 
that up to 2 of the following 4 features may be present- 1) 
increased cellularity, 2) blurring of papillary pattern, 3) 
nuclear plemorphism, 4) area of necrosis but these features 
are not necessary to diagnose atypical CPP. 
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 Choroid plexus carcinoma is WHO grade III tumour with 
invasive borders that may appear haemorrhagic, solid and 
necrotic. 
 Histologically CPC shows signs of malignancy. As per one 
study, signs of malignancy included at least 4 of the 
following 5 features- 
1) Frequent mitoses (>5 per 10 HPF), 
2) Increased cellularity,  
3) Blurring of papillary pattern,  
4) Nuclear plemorphism, 
5) Necrotic areas 
 CPC can mimic as metastatic carcinoma. Therefore various 
immunostains are needed for a conclusive opinion. 
 Papillary craniopharyngioma is WHO grade I tumour. 
Grossly these are solid well circumscribed tumours which 
shows absence of calcification and cholesterol-rich 
machinery oil like material. Histologically these tumours 
have well differentiated monomorphous squamous 
epithelium lacking surface maturation. These tumours also 
have wet keratin and picket-fence like palisades. 
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 Papillary meningioma is a WHO grade III tumour. Grossly 
they are firm, rubbery and rounded masses with dural 
attachment. These tumours have perivascular papillary 
pattern. 
 Ludwin et al, Kros et al, Pasquier et al(48,49,50) studied the 
aggressive nature of this tumour and found that invasion of 
brain and local invasion was seen in 75% of cases, 
metastases in 20%, and recurrence in 55% and death in 
roughly half. 
 Papillary tumour of pineal region corresponds to WHO 
grade II or III, but histological grading remain to be defined. 
These are well defined tumours grossly. Histologically this is 
an epithelial – appearing tumour which shows papillary 
pattern sometimes exhibiting ependymal like differentiation. 
The papillae are lined by large, pale to eosinophilic 
columnar cells. 
 Papillary glioneuronal tumours are indolent tumours which 
behave like a WHO grade I tumour but biologic progression 
has been reported in rare cases. Grossly it is a variably solid 
or cystic tumour. They show papillary and pseudo papillary 
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pattern lined by single or pseudo stratified cells with round 
nuclei. Focal collection of ganglion cells can be seen
(51)
 
 Astroblastomas show variable biologic behaviour. In this 
sufficient data is not available and so WHO grading has not 
been done. Grossly the tumour is grey- pink to tan in colour 
with foci of necrosis and haemorrhage. Tumour cells are 
arranged in papillary pattern showing unipolar cytoplasmic 
processes which connect the neoplastic cells to stromal 
blood vessels. 
 HISTOMORPHOLOGY OF METASTATIC PAPILLARY 
TUMOURS: 
 Metastasis to brain and spinal cord often produce grossly 
rounded, circumscribed, grey white to tan masses, most of 
them showing central necrosis with surrounding edema. 
 Collection of mucoid material can be seen in metastatic 
adenocarcinomas. 
 Histologically secondary nervous system tumours are very 
diverse as in primary tumours. Immunostains are needed for  
primary identification in unknown primary cases. 
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 ROLE OF IMMUNOHISTOCHEMISTRY IN NERVOUS 
SYSTEM TUMOURS: 
 Diagnostic neuropathology has improved more in recent past 
due to advance in immunohistochemistry based techniques. 
Newer reagents are continuously being developed against 
specific antigens associated with stages of cell lineage, 
oncogene, cell cycle and suppressor gene product or cell 
activation. Use of these antibodies will help us to define  
1) Nature of cellular maturation, 
2) Tissue differentiation 
3) Tumour progression  
4) Metastasis.  
 The continuing refinement and evolution of reagents and use 
of newer techniques result in tremendous improvement of 
histological classification. They are mainly used in difficult 
cases and in cases of unknown primary cases. 
 Immunohistochemistry helps not only to know about the 
ability of the tissue to express a particular antigen but also its 
exact cellular localization. This method also employs 
different antibodies to distinguish the antigenic differences 
between the cells. These antigenic differences can identify 
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a. Specific cellular lineage 
b. Functional differences between the cells 
c. Different subpopulation within one cell lineage 
d. Identify infections. 
 The tremendous progress in the field of immunohistochemistry 
allows the exploration of the molecular phenotypes of the 
developing CNS tumours.  
The most common methods used for immunohistochemistry are : 
1) Peroxidase – antiperoxidase method 
2) Avidin-biotin method 
 The main key requisite to this diagnostic modality is antibody 
specific to particular antigen. 
 The most important groups of antibodies are 
1. Intermediate filaments 
2. Neuroendocrine related proteins 
3. Markers with predominant expression in CNS tumour 
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4. Markers associated with suppressor genes, oncogenes and related 
gene products 
5. Markers to detect cell proliferation and cell death in CNS tumours 
6. Markers of historical significance and 
Intermediate filaments: 
The intermediate filament proteins are intercellular filaments which 
measures about 10micrometer in diameter and forms an important 
component of the cytoskeleton.  
There are 6 classes of intermediate filament proteins. 
1) Keratin - identifies epithelium 
  2) Vimentin – identifies 
 Mesenchymal cells 
 Astrocytes 
 Primitive neuroepithelial cells 
 Developing neuron 
  3) Glial fibrillary acidic protein (GFAP) identifies  
 Astrocytes 
 Nonmyelinating Schwann cells 
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 Ependymal cells 
 Peripherin identifies - neurones of CNS and peripheral 
nervous system 
Of these intermediate filaments, keratin, Vimentin and Glial 
fibrillary acidic protein are used for routine immunohistochemistry. 
 Vimentin is most widely expressed antigen in a variety of mature 
tissues and embryonic tissue. It is a 57-kD protein which was first 
isolated from a mouse fibroblast culture. In Latin vimentum means 
describing an array of flexible rods from which its name was derived. 
This protein is considered to be the main member of the intermediate 
filament family. Most of the time, when 2 or more IFPs are co expressed 
by a cell line or neoplasm, Vimentin is almost always one of them which 
is not considered to be cell type-specific. Positivity of vimentin denotes 
presence of antigen within the cells. 
 Glial fibrillary acidic protein (GFAP) is a useful marker for 
nervous system astroglial cells. This 51-kD protein is the major 
component of astrocytes and ependymal cells which is not 
expressed by mature oligodendroglial cells. 
 Firstly it is not specific for astroglial cells. 
 Secondly there is considerable interlaboratory variation. 
24
 Third problem is that the neoplastic astroglial cell and an entrapped 
reactive one cannot be differentiated. 
 Fourth, there is no reliable correlation between the degree of GFAP 
expression and the tumour anaplasia. 
 Cytokeratins (CK) are the most common intermediate filament. It 
is a marker of epithelium and its neoplasms. In CNS, it 
differentiates primary high-grade tumour from poorly 
differentiated metastatic carcinoma and also seen in chordomas, 
meningiomas, gliosarcomas, many astrocytomas, and 
oligodendrogliomas. 
  Carcino embryonic antigen (CEA) is  a 180-kD glycoprotein. 
Adenocarcinomas of the lung, colon, stomach, pancreas, biliary 
tree, urinary bladder, paranasal sinuses, endocervix, sweat glands, 
and breast are typically positive for CEA antibodies. 
Adenocarcinomas of prostate, kidney, endometrium, adrenal gland 
along with mesothelioma and serous ovarian tumors essentially 
negative for CEA antibody. 
 Epithelial membrane antigen (EMA) is eencoded by the MUC1 
gene on chromosome 1. Epithelial membrane antigen is a 
transmembrane glycoprotein of the breast mucin complex. Its 
expression is increased in carcinomas
 (81, 82)
. The use of EMA 
25
antibody is in the detection of epithelial differentiation, as a 
supplement to the cytokeratins. 
 So, to differentiate between a primary and a secondary CNS 
tumour, the antibody panel should have CK, CEA and GFAP.  
Neuroendocrine related proteins: 
Two proteins are rather consistently expressed by the 
neuroendocrine lineage 
a. Neuron specific enolase 
b.  Synaptophysin 
c. Chromogranin.  
A. Neuron specific enolase is one of the first markers for 
neuroendocrine system, but extensive cross reaction of Gamma-
subunit with the Beta-subunit of NSE in many non-neuroendocrine 
cells limits the advantages of this antibody. 
B. Synaptophysin is major calcium – binding protein present in the 
synaptic-vesicle membrane and it cross-reacts with other granule 
associated proteins. It is demonstrated in Medulloblastomas, 
neurocytomas, ganglioglioms, pineocytomas, ganglioneuromas and 
some oligodendrogliomas. Many peripheral neuroendocrine 
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tumours like pheochromocytoma, small cell carcinoma of lung, 
carcinoid and pituitary adenomas also express this antigen. 
C. Chromogranin A is expressed by dense-core vesicles of 
neuroendocrine cells. Most neuroendocrine tumours outside CNS 
express this antigen. In CNS only ganglioglioma consistently 
expresses this antigen. These are expressed in retinoblastoma and 
medulloblastoma with variable intensity.  
Germ cell tumour markers: 
Germ cell tumours are not uncommon in central nervous system. 
The primordial germ cell disseminates most frequently from mediastinum 
and diencephalopineal region. The germ cell tumour markers used in 
CNS tumours are 
1) Alpha feto protein – AFP 
2) Placental alkaline phosphatase – PLAP 
3) Beta Human chorionic gonadotrophin – BHCG 
More over Cytokeratin, Epithelial membrane antigen (EMA) and 
Vimentin are often needed. 
Miscellaneous markers: 
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S-100 protein: This is first isolated from CNS in 1965. It is 
localized in the cytoplasm and nucleus of astrocytes, oligodendrocytes 
and Schwann cells. Few neurons also have this protein. Its use is rather 
limited by the vastness of its neural positivity. The main use is in 
identifying MPNST from therapeutic application in out so far future. 
The tumour markers are very important diagnostic tools even 
though they have many pitfalls which one should be aware of. The 
interpretation of immunohistochemistry results should always be done in 
correlation with the morphology, proper clinical and radiological history. 
The future of immunohistochemistry is aimed at not only for the 
diagnosis and prognostication of the tumours but also being able to 
analyse and predict upon the probable response to various 
chemotherapeutic agents. 
ROLE OF IMMUNOHISTOCHEMISTRY IN PAPILLARY 
NEOPLASMS: 
 Primary papillary tumours: 
 Myxopapillary ependymoma: 
 Myxopapillary ependymoma shows GFAP, Vimentin and S-100 
positivity but cytokeratin reactivity is absent. 
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 Coffin et al(52) studied the tumours to be distinguished from 
myxopapillary ependymoma. These include myxoid 
chondrosarcoma, mesothelioma, chordoma, and papillary 
adenocarcinoma. In this cytokeratin negativity and GFAP 
positivity will confirm the diagnosis. 
 Ang et al(53) studied 25 cases of papillary tumours in those 2 cases 
of myxopapillary ependymoma showed GFAP and Vimentin 
positivity. 
 Two cases of myxopapillary ependymoma in Mannoj et al(54) study 
showed GFAP positivity and CK negative. 
 Papillary ependymoma: 
 Papillary ependymomas show GFAP positivity and Nestin 
positivity. EMA and CK are negative. 
 4 cases of papillary ependymoma in a study by Ang et al(53) showed 
GFAP, S-100 and Vimentin positivity in all 4 cases. 
 Mannoj et al(54) studied in 4 cases of papillary ependymoma two 
tumours showed CK positivity. This positive staining was observed 
in apical part. 
 Choroid plexus tumours: 
 In choroid plexus papilloma cytokeratin and Vimentin are 
expressed in all cases. 55-90% of cases are S-100 positive. GFAP 
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is absent in normal choroid plexus epithelium but 22-55% of CPP 
shows positivity. In this 74% of CPP showed CK 7positivity and 
CK 20 negativity.
(55)
 
 Hasselblatt et al(56) studied choroid plexus tumours and found out 
that transthyretin was positive in 70% of CPP.  
 Ang et al(53) showed that in 5 cases of choroid plexus papilloma all 
5 showed CK positivity, 4 showed S-100 positivity and 2 cases 
showed focal GFAP positivity. 1 case of choroid plexus carcinoma 
studied showed CK, S-100 positivity and focal GFAP positivity. 
 In a study by Mannoj et al(54) CPP cases showed CK-positivity. 3 
cases were GFAP positive. In CPC solid, areas were negative for 
CK. 
 Papillary craniopharyngioma: 
 In contrast to adamantinomatous variant of raniopharyngioma, 
papillary variant does not show beta catenin mutation. 
 Papillary meningioma: 
 All meningiomas show Vimentin positivity.EMA is also positive in 
majority of the meningiomas. 
 In study by Ang et al(53), papillary meningioma showed only 
Vimentin positivity. 
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 Other papillary tumours: 
 Papillary tumour of pineal region showed CK positivity and focal 
GFAP, S-100 and Vimentin positivity. 
 Astroblastomas were positive for Vimentin, GFAP and S-100. 
They are negative for CK. 
 Metastatic papillary tumours: 
 Immunohistochemistry is very useful in identification of unknown 
primary. Some of the primary CNS tumours like CPC can produce 
difficulty in diagnosis. In histology they mimic metastatic deposits. 
In these settings IHC is needed 
1) To differentiate primary tumour from metastasis 
2) To identify the primary site in metastasis 
 No single immunostain is useful. So use of antibody panel is 
needed to identify the primary. 
 Ang et al(53) studied 25 papillary neoplasms of nervous system. In 
this metastatic papillary adenocarcinoma comprised 7 cases. They 
used a panel of antibodies (GFAP, S-100, CEA, CK, VM, 
prealbumin). All 7 metastatic tumours showed strong cytoplasmic 
CK staining. 6 cases showed CEA positivity. None of the primary 
tumours showed CEA positivity. 
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 In our study we used GFAP, Vimentin, S-100, EMA, CEA, 
Pancytokeratin, thyroglobulin, ER,PR,NSE for identification of 
primary papillary tumour origin and to differentiate primary 
papillary tumour from papillary metastases. 
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MATERIALS AND METHODS 
This study is a retrospective- cum- prospective descriptive study of 
papillary neoplasms of nervous system conducted in Department of 
Neuropathology, Madras Medical College and Rajiv Gandhi Government 
General hospital, Chennai during the period of January 2007 to December 
2011. 
Source of data: 
 The papillary neoplasms reported in Department of 
Neuropathology, Madras Medical College during the period of 
January 2007 to December 2011 from the Department of 
Neurosurgery, Rajiv Gandhi Government General hospital. A total 
62 papillary tumour neurosurgical specimens were received during 
the study period. 
Inclusion Criteria: 
 All the nervous system neoplasms showing papillary pattern 
irrespective of their origin whether it is primary or secondary. 
Exclusion criteria: 
1. Recurrent papillary tumours 
2. Non neoplastic conditions 
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3. Cases with inadequate material from the tumour for doing both 
H&E and immunohistochemistry 
 
METHOD OF DATA COLLECTION: 
 Detailed history of the cases regarding age, sex, symptoms, 
laterality of symptoms, radiological findings, history of previous 
surgery for the same symptoms, details of gross characteristics 
were obtained for all the 62 neoplasms with papillary pattern from 
Surgical Pathology records from neuropathology. Freshly cut 
sections and Hematoxylin Eosin stained 4 µ thick sections of the 
paraffin tissue blocks of this specimens were reviewed and graded 
using the WHO grading criteria. (Annexure II). Out of 62 cases 
blocks were available for 56 cases of papillary neoplasms. All the 
56 cases were selected from the total cases and their representative 
formalin fixed paraffin embedded tissue samples were subjected to 
Immunohistochemistry with a panel of 6 markers and 2 to 3 
additional markers. The results were recorded with photographs.  
Follow up data of some of the patients regarding the adjuvant 
therapy, recurrence, disease free survival were obtained from 
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Medical Records Section of Department of Oncology and 
neurosurgery 
IMMUNOHISTOCHEMICAL EVALUATION: 
 Immunohistochemical analysis using panel of markers including  
pan cytokeratin, Glial Fibrillary Acidic Protein, S-100 protein, 
Vimentin, carcino embryonic antigen and Epithelial membrane 
antigen were done in paraffin embedded tissue samples using 
Supersentive polymer HRP system based on non biotin polymeric 
technology. Due to economic constraints, immunohistochemistry 
for secondary metastatic deposits were done only in selected cases 
to identify the origin of primary. Thyroglobulin, estrogen receptor 
and progesterone receptor were the additional markers used in this 
study to identify the primary. 
 Sections with a thickness of 4 µ from selected formalin fixed 
paraffin embedded tissue samples were transferred onto gelatin 
coated slides. Heat induced antigen retrieval was done. The antigen 
is bound with mouse monoclonal antibody (Biogenex) against pan 
cytokeratin, Glial Fibrillary Acidic Protein, S-100 protein, 
Vimentin, carcino embryonic antigen, Epithelial membrane 
antigen, Thyroglobulin, estrogen receptor and progesterone 
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receptor and then detected by the addition of secondary antibody 
conjugated with horse radish Peroxidase-polymer and 
Diaminobenzidine substrate 
ANTIBODIES FOR IHC 
Antigen Vendor Species Dilution 
Positive 
control 
Pan cytokeratin BIOGENEX Mouse 
Ready to 
use 
Skin  
Glial Fibrillary 
Acidic Protein 
BIOGENEX Mouse 
Ready to 
use 
Normal Brain 
parenchyma 
S-100 BIOGENEX Mouse 
Ready to 
use 
Skin  
Vimentin BIOGENEX Mouse 
Ready to 
use 
Uterus  
Carcino 
Embryonic 
Antigen 
BIOGENEX Mouse 
Ready to 
use 
Colon  
Epithelial 
Membrane 
Antigen 
BIOGENEX Mouse 
Ready to 
use 
Kidney  
Thyroglobulin BIOGENEX Mouse 
Ready to 
use 
Thyroid  
Estrogen 
receptor 
BIOGENEX Mouse 
Ready to 
use 
Breast  
Progesterone 
receptor 
BIOGENEX Mouse 
Ready to 
use 
Breast  
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The step by step Immunohistochemistry procedure was given 
below in detail. 
PREPARATION OF SLIDES: 
1. Sections with a thickness of 4 µ were cut from formalin fixed 
paraffin embedded tissue samples and transferred to gelatin-
chrome alum coated slides. 
2. The slides were incubated at 58ºC for overnight. 
3. The sections were deparaffinised in xylene for 15 minutes x 2 
changes. 
4. The sections were dehydrated with absolute alcohol for 5 minutes x 
2 changes. 
5. The sections were washed in tap water for 10 minutes. 
6. The slides were then immersed in distilled water for 5 minutes. 
ANTIGEN RETRIEVAL: 
 
7. Heat induced antigen retrieval was done with microwave oven in 
appropriate temperature with appropriate buffer for 20 to 25 
minutes. 
8. The slides were then cooled to room temperature and washed in 
running tap water for 5 minutes. 
37
9. The slides were then rinsed in distilled water for 5 minutes. 
10. They were washed with appropriate wash buffer (phosphate 
buffer) for 5 minutes x 2 changes. 
11. Peroxidase block was applied over the sections for 10 minutes. 
12. The slides were washed in phosphate buffer for 5 minutes x 2 
changes.  
13. Sections were covered with power block for 15 minutes. 
 
ANTIBODY APPLICATION: 
 
14. The sections were drained (without washing) and appropriate 
primary antibody was applied over the sections and incubated for 
45 minutes. 
15. The slides were washed in phosphate buffer for 5 minutes x 2 
changes. 
16. The slides were covered with Super Enhancer for 30 minutes. 
17. The slides were washed in phosphate buffer for 5 minutes x 2 
changes. 
18. The slides were covered with SS Label for 30 minutes. 
19. The slides were washed in phosphate buffer for 5 minutes x 2 
changes. 
38
CHROMOGEN APPLICATION: 
 
20. DAB substrate was prepared by diluting 1 drop of DAB 
chromogen to 1 ml of DAB buffer. 
21. DAB substrate solution was applied on the sections for 8 minutes. 
22. The slides were washed in phosphate buffer solution for 5 minutes 
x 2 changes. 
23. The slides were washed well in running tap water for 5 minutes. 
24. The sections were counterstained with Hematoxylin stain for 2 
seconds (1 dip). 
25. The slides were washed in running tap water for 3 minutes. 
26. The slides were air dried, cleared with xylene and mounted with 
DPX.     
INTERPRETATION & SCORING SYSTEM: 
 The immunohistochemically stained slides were analyzed for the 
presence of reaction, cellular localization (nuclear /cytoplasmic 
/membranous), percentage of cells stained and intensity of reaction. 
In this study IHC staining was graded by using semi quantitative 
scale ranging from 0 (no immunoreactive cells) to 4+ (75-100% of 
the neoplastic cells are immunostained) The symbols 1+, 2+, and 
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3+ refer to the immunostaining of up to 25%, 25-50%, and 50-75% 
of the neoplastic cells, respectively
(67)
 
*
 
STATISTICAL ANALYSIS: 
 The statistical analysis is performed using statistical package for 
social science software version 11.5. Expression of each marker 
indicates the cell of origin in primary and secondary tumours.  
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OBSERVATION AND RESULTS 
In the study period of 5years from January 2007 to December 
2011, a total of 2932 specimens were received in the Neuropathology 
department, Madras Medical College for histological examination. Total 
numbers of neoplasms received were 2333;of these tumours with 
papillary pattern accounted for 62 cases with a percentage of 2.66 %. The 
total number of non neoplastic cases was 593. The ratio of neoplastic and 
non neoplastic cases was 4.3:1. Metastatic papillary tumours are the most 
common nervous system tumour with papillary pattern. Out of 62 cases 
metastasis constituted 39 cases (62.90%) In this study primary nervous 
system tumours with papillary pattern constituted 23 cases (37.10%). 
(Table 1 Chart 1) 
TABLE - 1 
ORIGIN-WISE DISTRIBUTION OF NERVOUS SYSTEM 
NEOPLASMS WITH PAPILLARY PATTERN 
S.no Origin Number of cases Percentage 
1 Primary 23 37.10% 
2 Secondary 39 62.90% 
3 Total cases 62 100% 
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0-10 yrs was the most common age group for the primary papillary 
neoplasms in this study. Out of 23 cases 0 to 10 year age group 
constituted 7 cases with relative percentage of about 11.29% among 
overall papillary tumours, and 30.44% among primary papillary tumours. 
Next most common age group was 11 to 20 years which included 6 cases 
with a relative percentage of 9.68% among papillary tumours and 26.09% 
among primary papillary tumours. Least common age group was 4
th
 to 7
th
 
decade which included 3 cases with a relative percentage of 4.84% 
overall and 13.04% among primary papillary tumours. The age wise 
distribution of primary papillary tumours is shown in this table. (Table 2 
Chart 2) 
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 TABLE – 2 
AGE-WISE DISTRIBUTION OF PRIMARY PAPILLARY 
TUMOURS OF NERVOUS SYSTEM 
S. 
no 
Age in years 
(primary) 
Number of 
cases 
% (among 
primary papillary 
tumours) 
% 
(overall) 
1 0 to 10 7 30.44% 11.29% 
2 11 to 20 6 26.09% 9.68% 
3 21 to 30 4 17.39% 6.45% 
4 31 to 40 3 13.04% 4.84% 
5 41 to 50 0 0 0 
6 51 to 60 3 13.04% 4.84% 
7 61 to 70 0 0 0 
8 Total cases 23 100% 37.10% 
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Metastatic tumours are most common in 3
rd
 to 6
th
 decade with peak 
age group between 51 to 60 years which constitutes about 13 cases with 
relative percentage of 20.97% among overall papillary tumours of 
nervous system, 33.33% among secondary deposits with papillary 
pattern. Least common age groups are 1
st
 two decades (0%). Age wise 
distribution of metastatic tumours with papillary pattern is shown in this 
table. (Table 3 chart 3) 
TABLE – 3 
AGE WISE DISTRIBUTION OF METASTATIC PAPILLARY 
TUMOURS OF NERVOUS SYSTEM 
S.no 
Age in 
years 
Number of 
cases 
Percentage  (2* 
papillary 
tumours) 
Percentage 
(Overall) 
1 0 to 10 0 0 0 
2 11 to 20 0 0 0 
3 21 to 30 3 7.69% 4.83% 
4 31 to 40 6 15.38% 9.68% 
5 41 to 50 11 28.22% 17.74% 
6 51 to 60 13 33.33% 20.97% 
7 61 to 70 6 15.38% 9.68% 
8 Total cases 39 100% 62.90% 
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Males are most commonly affected in primary and secondary 
nervous system tumours with relative overall percentage of 27.42% in 
primary tumours, 38.71% in secondary tumours.  Male : Female ratio for 
papillary tumour was 2:1.This table shows sex wise distribution of 
primary and secondary papillary tumours of nervous system. (Table 4 and 
Chart 4), (Table 5 and Chart 5) 
TABLE – 4 
SEX WISE DISTRIBUTION OF PRIMARY PAPILLARY 
TUMOURS NERVOUS SYSTEM 
S.no 
Sex 
(Primary) 
Number of 
cases 
% (Among 1* 
papillary 
tumours) 
% 
(Overall) 
1 Male 17 73.91% 27.42% 
2 Female 6 26.09% 9.68% 
3 Total cases 23 100% 37.10% 
 
TABLE – 5 
SEX WISE DISTRIBUTION OF METASTATIC PAPILLARY 
TUMOURS OF NERVOUS SYSTEM 
S.no 
Sex 
(Secondary) 
Number of 
cases 
% (Among 2* 
papillary tumours) 
% 
(Overall) 
1 Male 24 61.54% 38.71% 
2 Female 15 38.46% 24.19% 
3 Total cases 39 100% 62.90% 
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In this study the most common site for primary papillary tumour 
was spinal cord which constituted about 9 cases (overall 14.52%) with 
relative percentage of about 39.12% among primary papillary tumours. 
Other common sites were lateral ventricle and cerebrum each constituting 
4 cases (6.45%). Sellar region was the least common site (3.22%) with an 
incidence 8.70% among primary tumours. Site wise distributions of 
primary papillary tumours are shown in this table. (Table 6 Chart 6). 
TABLE – 6 
SITE WISE DISTRIBUTION OF PRIMARY PAPILLARY 
TUMOURS OF NERVOUS SYSTEM 
S.no Site (primary) 
Number of 
cases 
% (Among 1* 
papillary 
tumours) 
% 
(Overall) 
1 Cerebrum 4 17.39% 6.45% 
2 Posterior fossa 2 8.70% 3.23% 
3 
Lateral 
ventricle 
4 17.39% 6.45% 
4 Third ventricle 2 8.70% 3.22% 
5 Spinal cord 9 39.12% 14.52% 
6 Sellar 2 8.705 3.23% 
7 Total cases 23 100% 37.10% 
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In this study cerebrum was the most common site for metastatic 
deposits with papillary pattern which constituted 29 cases with overall 
percentage of 46.77% and 74.36% among secondary tumours. Least 
common site was ventricles (0%). The site of distribution of metastatic 
deposits with papillary pattern is shown in this table. (Table 7 Chart 7). 
TABLE – 7 
SITE WISE DISTRIBUTION OF METASTATIC DEPOSITS IN 
NERVOUS SYSTEM WITH PAPILLARY PATTERN 
S.no 
Site 
(Secondary) 
Number 
of cases 
%  (Among 2* 
papillary 
tumours 
% 
(Overall) 
1 Cerebrum 29 74.36% 46.77% 
2 Posterior fossa 7 17.95% 11.3% 
3 Lateral 
ventricle 
0 
0 
0 
4 Third ventricle 0 0 0 
5 Spinal cord 3 7.69% 4.83% 
6 Sellar 0 0 0 
7 Total cases 39 100% 62.90% 
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In cerebrum, the frontal lobe was the most common site for 
secondary deposits with papillary pattern which constituting 13 cases 
(44.83%). Temporo parietal region was the next common site (24.14%). 
Lobe wise distributions of metastatic deposits with papillary pattern are 
shown in this table. (Table 8 and Chart 8) 
 
TABLE – 8 
CEREBRAL LOBE WISE DISTRIBUTION OF METASTATIC 
TUMOUR WITH PAPILLARY PATTERN 
S.no Lobes of cerebrum 
(secondary) 
Number of cases Percentage 
1 Frontal 13 44.83% 
2 Temporal 2 6.90% 
3 Parietal 2 6.90% 
4 Temporo parietal 7 24.14% 
5 Parieto occipital 5 17.24% 
6 Total cases 29 100% 
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Histomorphological wise, metastatic papillary adenocarcinomatous 
deposit was the most common type which constituted about 39 cases 
(62.90%). Among primary papillary tumours, myxopapillary 
ependymoma constituted 7cases (8.06%). Histomorphological 
distributions of tumours with papillary pattern are shown in this table. 
(Table 9 Chart 9). 
TABLE – 9 
HISTOMORPHOLOGICAL DISTRIBUTION OF NERVOUS 
SYSTEM TUMOURS WITH PAPILLARY PATTERN 
S.no Histomorphology 
Number of 
cases 
Percentage 
1 Metastatic papillary adeno 
carcinomatous deposits 
39 62.90% 
2 Myxopapillary 
ependymoma 
7 11.29% 
3 Papillary meningioma 5 8.06% 
4 Choroid plexus papilloma 2 3.23% 
5 Choroid plexus papilloma 
with atypia 
2 3.23% 
6 Choroid plexus carcinoma 2 3.23% 
7 Papillary 
craniopharyngioma 
2 3.23% 
8 Others 3 4.83% 
9 Total cases 62 100% 
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In this study the primary site for metastatic deposits with papillary 
pattern was known for 29 cases. Lung was the primary site for 20 cases 
(51.28%). Next was thyroid and included 4 cases (10.26%). 10 cases 
(25.64%) were unknown primary when presented with metastasis or 
details were not available. (Table 10 Chart 10) 
TABLE – 10 
PRIMARY TUMOUR WISE DISTRIBUTION OF METASTATIC 
DEPOSITS WITH PAPILLARY PATTERN 
S.no Primary tumour Number of cases Percentage 
1 LUNG  20 51.28% 
2 THYROID 4 10.26% 
3 GIT(colon) 2 5.13% 
4 FGT 2 5.13% 
5 BREAST 1 2.56% 
6 UNKNOWNPRIMARY/ 
DETAILS 
UNAVAILABLE 
10 25.64% 
7 TOTAL CASES 39 100% 
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In this study among the 39 cases of metastatic deposits, males (24 
cases) were most commonly affected than females (15 cases). Among the 
20 cases of lung carcinoma, 15 cases (38.47%) were males and 5 cases 
(12.82%) are females. This is shown in (Table 11 and Chart 11). 
TABLE – 11 
SEX WISE DISTRIBUTION OF PRIMARY TUMOURS 
PRODUCED DEPOSITS IN NERVOUS SYSTEM 
S.no Primary tumour Male 
(no) 
% Female(no) % 
1 LUNG  15 38.47% 5 12.82% 
2 THYROID 1 2.56% 3 7.69% 
3 GIT 2 5.13% 0 0 
4 FGT 0 0 2 5.13% 
5 BREAST 0 0 1 2.56% 
6 UNKNOWN/PRIMARY 
DETAILS 
UNAVAILABLE 
6 15.38% 4 10.26% 
7 TOTAL CASES 24 61.54% 15 38.46% 
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WHO GRADE I tumour constituted 11 cases (47.83%). WHO a 
GRADE III tumour constituted 13.04%.Grading of primary papillary 
tumours was shown in this table. (Table 12 and Chart 12) 
TABLE – 12 
WHO GRADE WISE DISTRIBUTION OF PRIMARY NERVOUS 
SYSTEM TUMOURS WITH PAPILLARY PATTERN 
S.no WHO GRADE Number of 
cases 
Percentage 
1 WHO GRADE I 11 47.83% 
2 WHO GRADE II 3 13.04% 
3 WHO GRADE III 7 30.43% 
4 WHO GRADE IV 2 8.70% 
5 TOTAL CASES 23 100% 
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We used a panel of IHC markers for 56 cases. Blocks were not 
available for 2 cases of papillary meningioma, one case of choroid plexus 
carcinoma, one case of papillary ependymoma, one case of choroid 
plexus carcinoma with focal atypia and one case of PNET. GFAP showed 
positivity in 6 cases (10.70%) of Myxopapillary ependymoma, 1 case of 
papillary meningioma and one case of ependymoblastoma. All 39 cases 
(69.64%) of secondary metastatic deposits showed GFAP negativity. 
(Table 13) 
TABLE – 13 
 
GFAP EXPRESSION IN NERVOUS SYSTEM TUMOURS WITH 
PAPILLARY PATTERN 
 
S.no Histomorphology 
GFAP+VE 
(NO) 
% 
GFAP-
VE(NO) 
% 
1 Myxopapillary 
ependymoma 
6 10.70% 1 1.79% 
2 Papillary meningioma 1 1.79% 2 3.57% 
3 Choroid plexus 
papilloma 
0 0 2 3.57% 
4 Choroid plexus 
papilloma with focal 
atypia 
0 0 1 1.79% 
5 Choroid plexus 
carcinoma 
0 0 1 1.79% 
6 Papillary variant of 
craniopharyngioma 
0 0 2 3.57% 
7 Ependymoblastoma 1 1.79% 0 0 
8 Metastatic papillary 
adeno carcinomatous 
deposits 
0 0 39 69.64% 
9 Total 9 14.28% 47 85.72% 
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This study showed pan cytokeratin positivity in 39 cases (69.64%) 
of metastatic deposits, 2 cases (3.57%) of choroid plexus papilloma and 
one case of choroid plexus papilloma with focal atypia. (Table 14) 
TABLE – 14 
CYTOKERATIN EXPRESSION IN NERVOUS SYSTEM 
TUMOURS WITH PAPILLARY PATTERN 
S.no Histomorphology 
CK+VE 
(NO) 
% 
CK-
VE(NO) 
% 
1 Myxopapillary 
ependymoma 
0 0 7 12.5% 
2 Papillary meningioma 0 0 3 5.36% 
3 Choroid plexus 
papilloma 
2 3.57% 0 0 
4 Choroid plexus 
papilloma with focal 
atypia 
1 1.79 0 0 
5 Choroid plexus 
carcinoma 
0 0 1 1.79% 
6 Papillary variant of 
craniopharyngioma 
0 0 2 3.57% 
7 Ependymoblastoma 0 0 1 1.79% 
8 Metastatic papillary 
adeno carcinomatous 
deposits 
39 69.64% 0 0 
9 Total 42 75% 14 25% 
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S-100 protein studied showed positivity in 2(3.57%) cases of 
choroid plexus papilloma and one case of choroid plexus papilloma with 
focal atypia. All other tumours were negative for S-100 protein. (Table 
15). 
TABLE – 15 
S-100 PROTEIN EXPRESSION IN NERVOUS SYSTEM 
TUMOURS WITH PAPILLARY PATTERN 
S. 
no 
Histomorphology 
S-
100+VE
(NO) 
% 
S-100-
VE(NO) 
% 
1 
Myxopapillary 
ependymoma 
0 0 7 12.5% 
2 Papillary meningioma 0 0 3 5.36% 
3 
Choroid plexus 
papilloma 
2 3.57% 0 0 
4 
Choroid plexus 
papilloma with focal 
atypia 
1 1.79 0 0 
5 
Choroid plexus 
carcinoma 
0 0 1 1.79% 
6 
Papillary variant of 
craniopharyngioma 
0 0 2 3.57% 
7 Ependymoblastoma 1 1.79% 0 0 
8 
Metastatic papillary 
adeno carcinomatous 
deposits 
0 0 39 69.64% 
9 Total 3 5.36 53 94.64% 
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Vimentin studied in this study shows positivity in 3 cases of 
papillary meningioma and one case of myxopapillary ependymoma. All 
other tumours were negative for vimentin with in the tumour cells. (Table 
16). 
TABLE – 16 
VIMENTIN EXPRESSION IN PAPILLARY NEOPLASMS OF 
NERVOUS SYSTEM 
S. 
no 
Histomorphology 
VIM 
+Ve 
(NO) 
% 
VIM-
Ve 
(NO) 
% 
1 
Myxopapillary 
ependymoma 
1 1.79% 6 10.70% 
2 Papillary meningioma 3 5.36% 0 0 
3 Choroid plexus papilloma 0 0 2 3.57% 
4 
Choroid plexus papilloma 
with focal atypia 
0 0 1 1.79% 
5 
Choroid plexus 
carcinoma 
0 0 1 1.79% 
6 
Papillary variant of 
craniopharyngioma 
0 0 2 3.57% 
7 Ependymoblastoma 1 1.79% 0 0 
8 
Metastatic papillary 
adeno carcinomatous 
deposits 
0 0 39 69.64% 
9 Total 4 7.15% 52 92.85% 
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Carcino embryonic antigen showed positivity in all 39 cases of 
(69.64%) metastatic deposits. None of the primary tumours showed 
positivity. (Table 17). 
TABLE – 17 
CARCINO EMBRYONIC ANTIGEN IN PAPILLARY 
NEOPLASMS OF NERVOUS SYSTEM 
S. 
no 
Histomorphology 
CEA+Ve 
(NO) 
% 
CEA-
Ve 
(NO) 
% 
1 
Myxopapillary 
ependymoma 
0 0 7 12.5% 
2 Papillary meningioma 0 0 3 5.36% 
3 
Choroid plexus 
papilloma 
0 0 2 3.57% 
4 
Choroid plexus 
papilloma with focal 
atypia 
0 0 1 1.79% 
5 
Choroid plexus 
carcinoma 
0 0 1 1.79% 
6 
Papillary variant of 
craniopharyngioma 
0 0 2 3.57% 
7 Ependymoblastoma 0 0 1 1.79% 
8 
Metastatic papillary 
adeno carcinomatous 
deposits 
39 69.64% 0 0 
9 Total 39 69.64% 17 
30.36
% 
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Epithelial membrane antigen studied showed positivity in 37 cases 
(66.07%) of metastatic deposits and one case of papillary meningioma. 
(Table 18). 
TABLE – 18 
EPITHELIAL MEMBRANE ANTIGEN EXPRESSION IN 
PAPILLARY NEOPLASMS OF NERVOUS SYSTEM 
S. 
no 
Histomorphology 
EMA+
Ve 
(NO) 
% 
EMA-
Ve 
(NO) 
% 
1 Myxopapillary 
ependymoma 
0 0 7 12.5% 
2 Papillary meningioma 1 1.79% 2 3.57% 
3 Choroid plexus 
papilloma 
0 0 2 3.57% 
4 Choroid plexus 
papilloma with focal 
atypia 
0 0 1 1.79% 
5 Choroid plexus 
carcinoma 
0 0 1 1.79% 
6 Papillary variant of 
craniopharyngioma 
0 0 2 3.57% 
7 Ependymoblastoma 0 0 1 1.79% 
8 Metastatic papillary 
adeno carcinomatous 
deposits 
37 66.07% 2 3.57% 
9 Total 38 67.86% 18 32.14% 
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In this study 4 cases of thyroid carcinoma metastasis showed 
thyroglobulin, CEA and CK positivity. Because of economic constraints 
other panels of antibodies to find out unknown primary was not used in 
this study. 
59
DISCUSSION 
Nervous system tumours are increasing in incidence in both developed 
and developing countries in the present era. Both adults and paediatric 
population show increasing occurrence of nervous system tumours.  
* EPIDEMIOLOGY OF NERVOUS SYSTEM TUMOURs IN 
GENERAL: 
* In the present study, histomorphological and immunohistochemical 
evaluation was done in 56 cases of papillary neoplasms and an attempt 
to differentiate each papillary neoplasm has been made with the use of 
a panel of IHC markers. 
* Madras Medical College being a tertiary referral centre, the relative 
percentage of nervous system tumours among neuropathology samples 
was 79.48%. 20.22% were non neoplastic lesions. Among the nervous 
system tumours 62 cases were papillary neoplasms which constituted 
about 2.66%. 
* In this study Male: Female ratio of nervous system tumours was 2:1. 
* As per WHO statistics nervous system tumours account for about 
1.9% of overall tumour  incidence in males and 1.8% in females
(57)
. In 
paediatric age group, nervous system tumours are one of the most 
common solid tumours. As per Gurney et al
(58)
, CNS tumours are the 
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second most commonly distributed (20.7%) tumours after leukemia 
(23.2%). 
* In India as per ICMR
(59)
 statistics,  annual percentage change in brain 
cancer for males in Chennai was 3.0%, for females in Chennai was 
4.6%.  
* ICMR and WHO statistics are population based studies. This study is 
a tertiary care hospital based descriptive study. 
* This study showed that secondary metastatic carcinomatous deposits 
with papillary architecture constituted the most common nervous 
system tumours with an incidence of 62.90%. This is in concurrence 
with WHO statistics
(60)
, KE Smedby et al, Barnholtz-Sloan et al. 
(11,12)
 
* DESCRIPTIVE STUDY OF  PAPILLARY NEOPLAMS OF 
NERVOUS SYSTEM: 
* PRIMARY PAPILLARY NEOPLASMS:  
* Choroid plexus tumours: 
* Among 62 cases of papillary neoplasms, primary papillary 
tumours of nervous system constituted about 23 cases with a 
relative percentage of about 37%. 
* In this study choroid plexus tumour constituted about 6 cases 
with a  relative  percentage of about 10%. The peak age was 
between 1-15 years.  Among 6 cases of choroid plexus 
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tumour, 3 cases occurred in children ≤ 1 year of age with a 
relative percentage of 5%. This is in concurrent with WHO 
analysis
(61)
. 
* As per WHO
(61)
 among all brain tumours, choroid plexus 
tumours account for 0.3 – 0.6%; 2 – 4% of those occur in 
children less than 15 years of age. 10 % of those occur in 1
st
 
year of life. This is slightly higher than the present study. 
* Among 6 cases of choroid plexus tumours, 2 cases were 
choroid plexus papillomas ( WHO Grade I ) , 2 cases were 
choroid plexus papilloma with atypia ( WHO Grade II ) and 
2 cases were choroid plexus carcinoma ( WHO Grade III ) 
with relative percentage of about 3%. 
* As per Janish et al, Rickert et al and Wolff et al
(18, 19, 62)
 80% 
of Choroid plexus carcinoma arise in children in whom they 
constitute 20 – 40% of chroid plexus tumours. In the present 
study choroid plexus carcinoma constituted about 33%. This 
is in concurrence with the study of Janish et al
(18) 
* 
In this study among 6 cases, 4 cases presented as a lateral 
ventricle mass with a relative percentage of 67% among 
choroid plexus tumours. This is in concurrence with 
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WHO
(61)
 analysis. 2 cases presented as a third ventricle SOL 
(33%). 
* The overall male: female ratio was 1:1.  This ratio was 1:1 
for lateral ventricle tumours and 3
rd
 ventricle tumours. This 
is similar to the WHO
(61)
 study. 
* Myxopapillary ependymoma: 
* Myxopapillary ependymoma constituted the most common 
intra medullary neoplasm in this study. Among 7cases, 6 
were intra medullary, predominantly involving lumbar 
region. This is in concurrent with Kurt et al and Schiffer et 
al
(63,64) 
* Age range was 17 – 60 years with a male predominance. The 
male: female ratio was 6:1. This is in concurrent with 
Cervoni et al 
(17)
 study in which average age of presentation 
was 36 years with an age range of 6 to 82 years and Male: 
female ratio was about 2.2:1 
* In this study the most common site was lumbar region. As 
per WHO almost they exclusively occur in conus medullaris 
and filum terminale 
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* Papillary meningioma: 
* Ludwin et al,
(49)
 described the clinico pathologic features of 
17 cases and found that in comparison to other variants of 
meningiomas, PM was more frequent in children; 
8/17(47%). Mitoses were seen in 7/17(41%), local 
recurrences in 10/ 17(59%), brain invasion in 8/17(47%), 
and extra cranial metastasis in 4/17(23.5%). This was not in 
concurrence with the present study 
* Radhakrishnan et al.,
(65)
 reported 6 cases of PM all of which 
occurred in adults and most of them showed histological 
evidence of bone and brain invasion. This is in concurrence 
with the present study. 
* In the present study 5 cases were reported as papillary 
meningioma with a relative percentage of about 8%. All 
cases occurred in male patients with an age range of 18 to 53 
years. This is in concurrence with the study of 
Radhakrishnan et al
(65)
. Among 5 cases, 2 cases were 
papillary meningioma with rhabdoid differentiation. For 2 
cases paraffin blocks were not available.  
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* Papillary craniopharyngioma: 
* Among 62 papillary tumours, 2 cases were papillary 
craniopharyngioma. As per Adamson et al and Crotty et al
(23,24)
  
papillary craniopharyngioma occurs exclusively in adults with a 
median age range of 40 – 55 years. In the present study age 
range was 20 – 40 years. Compare to Crotty et al(24) the age 
group was younger in this study. Male: female ratio was 1:1. 
Sellar location was common in both studies. 
* Papillary ependymoma: 
* One case of papillary ependymoma was reported in 18 years 
male in lateral ventricle. Block was not available for 
histological and IHC analysis. 
* Metastatic papillary tumours of nervous system:  
* Metastatic papillary tumour included 39 cases with a relative 
percentage of 63 %. This is in concurrence with Barnholtz et 
al and K E Smedby et al
(11, 12). 
*
 
Among 39 cases, 24 cases were males with a relative 
percentage of 39%. 15 cases were female patients with a 
percentage of 24%. This is in concurrence with Barnholtz et 
al and Ksmedby et al
(11, 12). 
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*
 
Most common histological pattern was papillary adeno 
carcinomatous deposits. Among 39 cases, 28 cases were 
known primary. 23 cases with lung as primary constituted 
37% of papillary neoplasms; 59% of secondary 
adenocarcinomatous deposit; 1 case was thyroid carcinoma, 
2 cases were from GIT, 2 cases from ovarian malignancy. 
This is in concurrence with K E Smedby et al, Jill et al and 
WHO
(11,12,60)
. 
* Most common affected age group was between 41-60 years 
with a male predominance of about 24 cases with percentage 
of 39%; among metastasis percentage of males was 62%. 
This is in concurrence with WHO, & Jill et al 
(60,11)
. Females 
constituted 15 cases with an overall percentage of 24%, 
among metastasis 38%. 
* In this study, anatomical site wise analysis revealed that 
cerebrum was the most commonly affected region in the 
nervous system. Among 39 cases, 29 (47%) occurred in 
cerebrum, 7(11%) cases were in posterior fossa, 3(5%) cases 
were in spinal cord. This study is similar to WHO 
analysis
(60)
. 
66
* Among the cerebral lobes, frontal lobe was the most 
commonly affected lobe by metastasis. 13 cases occurred in 
frontal lobe followed by 7 cases in temperoparietal, and 5 
cases parieto occipital. This was in concurrence with WHO 
analysis and Jill et al
(60,11)
. 
* HISTO MORPHOLOGY OF PAPILLARY TUMOUS: 
* Primary papillary tumours: 
* Among 6 cases of choroid plexus tumour, 2 were WHO grade I 
choroid plexus papilloma, 2 cases were WHO grade II choroid 
plexus papilloma with atypia, 2 cases were WHO grade III 
choroid plexus carcinoma. CPP showed papillary pattern with 
central delicate fibro vascular core. These cores are lined by 
uniform single layer of cuboidal to columnar cells. Cells have 
oval to round, basally situated uniform nuclei. They have very 
low mitotic activity. Atypical choroid plexus papilloma showed 
increase mitotic activity. This is similar to WHO analysis 
(61) 
* CPC showed patternless diffuse sheets with ill defined papillary 
pattern. They showed >5 mitosis per 10HPF with increased 
nuclear pleomorphism. 
67
* All 7 myxopapillary ependymomas were WHO grade I tumour. 
They showed arrangement of cells in a papillary pattern around 
blood vessels. The cells were cuboidal to columnar with myxoid 
material in the background. This is similar to WHO analysis
(66)
. 
* Among 5 cases of papillay meningioma blocks were available 
for 3 cases only. These were WHO grade III tumours. They 
showed ill defined papillary pattern and diffuse pattern with 
adjacent brain parenchymal infiltration. In this 2 cases showed 
rhabdoid differentiation. Rhabdoid cells are plump oval cells 
with eccentrically placed nuclei with open chromatin and 
prominent nucleoli. Cytoplasm is waxy eosinophilic in nature. 
* 2 cases of papillary craniopharyngioma were reported. These 
are WHO grade I tumours. They showed well differentiated 
squamous epithelium in papillary pattern. 
* Metastatic papillary tumours: 
* Among 39 cases, 36 cases showed well defined papillary 
pattern of cells with central fibrovascular core. The cells 
lining the papillae were columnar cells showing stratification 
with increased N: C ratio and coarse hyperchromatic nuclei. 
Foci of necrosis were also seen.  
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* 2 cases of lung primary showed vague papillae and 
bronchiole alveolar pattern of cells. The cells are arranged in 
papillary pattern with oedematous fibro vascular core. The 
lining cells are low columnar with peg like appearance. 
* 2 cases of primary thyroid carcinoma showed papillary and 
follicular arrangement of cells. The cells are round to oval 
with clear nuclei with nuclear crowding and overlapping. 
The follicle contains colloid. 
* IMMUNO HISTOCHEMISTRY IN NERVOUS SYSTEM 
TUMOURS: 
* Primary papillary tumours: 
* In the present study we used a panel of 
immunohistochemical markers including Glial Fibrillary 
Acidic Protein, Pan Cytokeratin, Epithelial Membrane 
Antigen, S-100, Vimentin and carcino embryonic antigen. 
Blocks were not available for 2 cases of papillary 
meningioma, one case of choroid plexus carcinoma, one case 
of papillary ependymoma, one case of choroid plexus 
carcinoma with focal atypia and one case of PNET. 
* IHC staining was  graded similar to Doglioni et al
(67)
 by 
using semi quantitative scale ranging from -(no 
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immunoreactive cells) to 4+ (75-100% of the neoplastic cells 
are immunostained) The symbols 1+, 2+, and 3+ refer to the 
immunostaining of up to 25%, 25-50%, and 50-75% of the 
neoplastic cells, respectively.  
* In this study out of 4 cases of choroid plexus tumours, 3 
cases showed strong (4+) Cytokeratin positivity. These 3 
cases were CPP & ACPP. This is concurrence with Ang et 
al, Doglioni et al and Mannoji et al 
(53,67,54)
 study.CPC 
showed negativity for CK. This is differing from Ang et al
(53)
 
study.( Table 17,18,19) 
* In Ang et al
(53)
 study choroid plexus tumour showed focal 
GFAP positivity. This is in contradiction to the present study 
which showed  GFAP  negativity in all 6 cases of choroid 
plexus tumour. ( Table 17,18,19) 
* CPP and ACPP showed strong S-100 (3+) positivity. This is 
in concurrence with Ang et al study and Doglioni et al
(53,67)
. ( 
Table 17,18,19) 
* Vessel wall in the fibro vascular core showed strong 
Vimentin (4+) positivity. 
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* In concurrence with Ang et al
(53)
 study, all choroid plexus 
tumours showed complete negativity for CEA.( Table 
17,18,19) 
* None of the choroid plexus carcinoma showed S-100, 
Vimentin, EMA and CEA positivity. 
 
TABLE – 17 
IHC EXPRESSION IN CHOROID PLEXUS PAPILLOMA IN 
DIFFERENT STUDIES 
Choroid plexus 
papilloma(IHC) 
Ang et 
al
(53) 
Doglioni et 
al
(67) 
Mannoji 
et al
(54) 
Current 
study 
GFAP 2(5)- 
Focal 
6(13) 6(11) 0(2) 
CK 5(5) 8(13) 11(11) 2(2) 
S-100 4(5) 13(13) - 2(2) 
VIM 1(5) 11(13) - 0(2) 
CEA 0(5) - - 0(2) 
EMA - 8(13) - 0(2) 
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TABLE – 18 
IHC EXPRESSION IN CHOROID PLEXUS PAPILLOMA WITH 
FOCAL ATYPIA IN DIFFERENT STUDIES 
 
Choroid plexus papilloma 
with focal atypia (IHC) 
Ang et 
al
(53) 
Current study 
GFAP 1(1)- Focal 0(1) 
CK 1(1) 1(1) 
S-100 1(1) 1(02) 
VIM 0(1) 0(1) 
CEA 0(1) 0(1) 
EMA - 0(1) 
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TABLE – 19 
IHC EXPRESSION IN CHOROID PLEXUS CARCINOMA IN 
DIFFERENT STUDIES 
 
Choroid plexus 
carcinoma(IHC) 
Doglioni et 
al
(67) 
Mannoji et 
al
(54) 
Current 
study 
GFAP 2(3) 1(4) 0(1) 
CK 3(3) 4(4) 0(1) 
S-100 2(3) - 0(1) 
VIM 3(3) - 0(1) 
CEA - - 0(1) 
EMA 3(3) - 0(1) 
 
All 6 cases of myxopapillary ependymoma showed GFAP 4+ 
positivity in neuroepithelial cells and Vimentin 4+ positivity in blood 
vessels. This is in concurrence with Ang et al and Doglioni et al
(53, 67)
. 
One case showed Vimentin positivity in tumour cells with GFAP 
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negativity.  All 7 cases were non reactive for CK, S-100 and CEA. This is 
in concurrence with Ang et al and Doglioni et al
(53,67)
 study. 
TABLE – 20 
IHC EXPRESSION IN MYXOPAPILLARY EPENDYMOMA IN 
DIFFERENT STUDIES 
Myxopapillary 
ependymoma(IHC) 
Ang et al
(53) 
Mannoji et 
al
(54) 
Current 
study 
GFAP 2(2) 2(2) 6(7) 
CK 0(2) 0(2) 0(7) 
S-100 0(2) - 0(7) 
VIM 2(2) - 1(7) 
CEA 0(2) - 0(7) 
EMA - - 0(7) 
 
In this study IHC was done on 3 cases of papillary meningioma. 
One case was done in private hospital. Details of IHC were obtained from 
records. It showed strong 4+ for Vimentin and GFAP positivity was seen 
only in non neoplastic brain parenchyma. One case showed EMA 
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positivity. This is concurrent with Avninder et al, Radhakrishnan et al and 
Ludwin et al
(69,65,49)
. 
All cases papillary meningioma were non reactive for CK, EMA 
and CEA. This is similar to Ang et al study
(53)
. 
 
One case of ependymoblastoma showed GFAP, S-100, Vimentin 
4+ positivity, CK 2+ positivity. This is similar to Ehret et al, Cruz et al, 
Mannoji et al and Parkkila et al study.
(70,71,54,72).
 
 
All primary papillary tumours were non reactive for CEA. This is 
similar to Ang et al study
(53)
. 
 
* Metastatic papillary tumours: 
 
Among 39 cases of metastatic papillary tumours 36 showed CK 4+ 
positivity. 2 showed 2+ positivity and one showed (1+) positivity. All 39 
cases were non reactive for S-100.This is in concurrence with Ang et al 
and Gottschalk et al
(53,73)
 study. 
 
Similar to Ang et al
(53)
 study, all metastatic papillary tumours 
showed CK and CEA 4+ positivity. Thyroid carcinoma showed 4+ 
positivity for thyroglobulin and CEA. (Table 19) 
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TABLE – 19 
IHC EXPRESSION IN METASTATIC DEPOSITS IN DIFFERENT 
STUDIES 
Metastatic deposits(IHC) Ang et al
(53) 
Current study 
GFAP 0(7) 0(39) 
CK 7(7) 39(39) 
S-100 0(7) 0(39) 
VIM 0(7) 0(39) 
CEA 6(7) 39(39) 
EMA - 37(39) 
 
CEA is an useful marker to differentiate between primary and 
secondary tumours. This antibody is useful to differentiate the papillary 
neoplasms. 
* IHC SUMMARY: 
All myxopapillary ependymomas expressed both GFAP and VM, 
which were absent in all choroid plexus tumours. In contrast, all choroid 
plexus tumours showed anti-cytokeratin immunoreactivity that was 
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absent in the all myxo papillary ependymomas. 3 choroid plexus tumours 
also expressed S-100 P, thus differentiating them from metastatic 
carcinoma that showed negative immunostaining. Anti-CEA antisera 
immunoreactivity was seen in 39 tumours, whereas none of the primary 
CNS tumours expressed CEA. This is concurrent with Ang et al study
(53)
. 
 
STRENGTH AND LIMITATIONS OF THIS STUDY: 
* STRENGTH OF THIS STUDY: 
1. Study covers a period of 5 years done at a tertiary care 
hospital in south India. 
2. A papillary pattern seen in various CNS tumours. These 
have been studied extensively both histomorphologically and 
immunohistochemically in correlation with clinical 
parameters. 
3. A wide panel of markers have been studied which include 
a. Markers for primary papillary tumours 
b. Markers for differentiating primary and secondary 
papillary tumours 
c. Organ specific markers used for specific cases 
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* LIMITATIONS OF THIS STUDY: 
1. Study is hospital based, hence does not reflect the true 
incidence and prevalence in the community. 
2. Due to economic constraints, the entire panel of 
antibodies for each case could not be used. 
3. Follow up was not available and not analysed. 
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SUMMARY 
 A total of 2932 neuro surgical samples received at a tertiary 
care centre have been analysed. Of these the non neoplastic 
lesions constituted 20.23%, and neoplastic lesions of  
nervous system were 79.57%. 
 In a study period of 5 years, 62 cases of nervous system 
tumours with papillary pattern were subjected to histological 
and Immunohistochemical analysis to find out the usefulness 
of IHC in their diagnosis and differential diagnosis. The 
findings were correlated with WHO grading and analysis. 
 The relative frequency of nervous system tumours with 
papillary pattern among other nervous system tumours in 
Madras Medical College was 2.66% 
 Metastatic tumours with papillary pattern constituted 62.90% 
and this formed the most common tumours of nervous 
system. The peak age group was between 51 to 60 years with 
relative percentage of 20.97%. 
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 Males were most commonly affected in both primary and 
secondary papillary tumour with an overall percentage of 
27.42% in primary tumours, 38.71% in secondary tumours. 
 Primary lung carcinoma was the most common cause of 
nervous system metastasis in both males and females which 
constituted 20 cases and relative percentage of 51.28% 
among metastatic tumours. 
 Unknown primary/details not available cases constituted 
about 10 cases with percentage of 25.64%. 
 In primary nervous system tumours with papillary pattern 
most common age group was between 0 to 10 years with a 
relative percentage 11.29%. 
 In the 0-10 years age group, the most common tumours with 
papillary pattern were Choroid plexus tumour which 
constituted about 6 cases with relative overall incidence of 
9.68% and 26.09% among primary tumours. 
 Most common site for primary papillary tumour was spinal 
cord which constituted 9 cases (14.52%) with a relative 
percentage of 39.12% among primary papillary tumours. 
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 Myxopapillary ependymoma was the most common spinal 
cord papillary tumour which constituted about 7 cases with 
relative percentage of 30.43% among primary tumours. 
 Within the cerebral hemisphere ventricles were the most 
common site for primary papillary tumours which is 6 cases 
with relative percentage of 26.09%. 
 In metastatic papillary tumours cerebrum was the most 
common site with a relative percentage of 74.36% among 
secondary deposits. 
 In cerebrum, frontal lobe was the most common site for 
secondary deposits with papillary pattern which constituted 
13 cases with relative percentage of 44.83%. 
 WHO GRADE I tumours were the most common primary 
tumours which constituted 11 cases with relative percentage 
of 47.83%. 
 On Immunohistochemistry analysis GFAP expression was 
commonly seen in Myxopapillary ependymoma which 
included 6 cases with 10.70% relative incidence. 
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 Pan cytokeratin positivity was seen in all 39 (69.64%) cases 
of metastatic deposits and both cases 2 cases (3.57%) of 
choroid plexus papilloma. 
 S-100 protein studied showed positivity in both 2(3.57%) 
cases of choroid plexus papilloma. 
 Vimentin studied in this study showed positivity in all 
3(5.36%) cases of papillary meningioma and one case of 
myxopapillary ependymoma. All other tumours were 
negative for vimentin within the tumour cells. 
 Carcino embryonic antigen showed positivity in all 39 cases 
of (69.64%) metastatic deposits. None of the primary 
tumours showed positivity. 
 Epithelial membrane antigen studied showed positivity in 37 
cases (66.07%) of metastatic deposits and one case of 
papillary meningioma. 
 
 
 
82
CONCLUSION 
 The incidence of papillary neoplasms of nervous system in this 
study was 2.66%. 
 Metastatic deposits with papillary pattern constituted a higher 
percentage and older age group has higher incidence similar to 
western population. 
 Lung carcinoma producing brain metastasis constituted higher 
incidence similar to western population. 
 In younger age group most of the papillary tumours were choroid 
plexus tumours. 
 Most of the papillary meningiomas were seen in young adults. All 
patients were adult males. 
 Immunohistochemistry used in this study was useful to 
differentiate primary from secondary tumours and to diagnose 
primary papillary tumours. 
 Carcino embryonic antigen is an important marker to differentiate 
primary from secondary papillary tumours. 
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 We need more immunohistochemistry panels to know the primary 
site for secondary papillary tumours. 
 Use of these IHC markers aids us to know about individual tumour 
antigen expression, to diagnose difficult cases and for the correct 
management by clinicians.  
 RECOMMENDATIONS : 
 Taking into the consideration the paucity of data on CNS 
tumours, it is recommended to maintain a “Comprehensive 
CNS Tumour Registry” at the tertiary care hospital level. 
 This would help in generation of valuable input for proper 
planning and management. 
 Data from the registry will also help to get clear 
epidemiological picture of CNS tumours in Indian settings. 
 Further studies can be directed at adding further specific IHC 
markers and the role of proliferation indices to this study. 
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ANNEXURE I 
PROFORMA 
Case no :     OP/IP NO : 
Name  :     Biopsy No : 
Age  : 
Sex  : 
Clinical diagnosis : 
Symptoms  : 
H/O Recurrence : 
Risk factors any : 
CT/MRI findings : 
Site :    Contrast enhancement : 
Side :    Ventricle obstruction : 
Solid :    Cystic with mural nodule : 
Cystic : 
Type of surgery : 
Gross  : 
 Size: 
 Papillary excrescence: 
 Necrosis: 
Microscopy : 
Histological typing : 
WHO grading: 
 Grade I    Grade III 
 Grade II    Grade IV 
IHC RESULTS  :( Positivity & Semi quantitative Score 1-4+) 
 GFAP  : 
 CK   : 
 EMA   : 
 S-100   : 
 Vimentin  : 
 CEA   : 
 ER   : 
 PR   : 
 Thyroglobulin : 
  
ANNEXURE II 
WHO GRADING OF NERVOUS SYSTEM TUMOURS 
GRADE I : Neoplasms with low proliferative tendency 
GRADE II : Neoplasms with cytological atypia alone 
GRADE III : Neoplasms with anaplasia and mitotic activity 
GRADE IV : Neoplasms with micro vascular proliferation and/or    
    necrosis 
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Hyper 
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fossa 
SOL-K/C 
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ST 
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papillary 
adeno 
carcinomatou
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  - 
++
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++
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++
+ 
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compressi
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++
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++
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seizure, head 
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with 
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pattern 
  - 
++
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++
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++
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15 373/08 
42
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M 
head ache, 
vomiting 
Left 
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Secondary 
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adeno 
carcinomatou
s deposits 
  - 
++
+ 
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++
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+ 
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++
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hage & 
necrotic 
areas 
Secondary 
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carcinomatou
s deposits 
  - 
++
+ 
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++
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++
+ 
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Y 
M 
head ache, 
vomiting 
left 
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parietal 
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Secondary 
papillary 
adeno 
carcinomatou
s deposits 
  - 
++
++ 
- - 
++
+ 
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20 440/10 
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M 
slurring of 
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ache, 
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Left 
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parietal 
mixed 
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Secondary 
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carcinomatou
s deposits 
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++
+ 
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++
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head ache, 
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circumscri
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mass in 
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parietal 
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lung 
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MGBST 
Secondary 
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carcinomatou
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++
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- - 
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45
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seizure, head 
ache 
Right 
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s deposits 
  - ++ - - 
++
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++
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40
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head ache, 
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right 
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++
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++
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++
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++
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++
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++
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carcinomatou
s deposits 
  - 
++
++ 
- - 
++
+ 
++
+ 
      
31 26/09 
60
Y 
F 
head ache, 
vomiting 
Left 
Parieto 
ccipital 
SOL-K/C 
of lung 
carcinoma 
MGWS
T & 
MGBST 
Papillary 
carcinoma 
thyroid 
deposits 
  - 
++
++ 
- - 
++
+ 
++
+ 
++++     
32 30/09 
45
Y 
F 
sudden 
weakness 
Right 
parietal 
SOL-K/C 
of FGT 
malignanc
y- Ovary 
MGBST 
Secondary 
papillary 
adeno 
carcinomatou
s deposits 
  - 
++
+ 
- - 
++
+ 
++
+ 
      
33 166/09 
65
Y 
F 
seizure, head 
ache 
Multiple 
hypo 
dense 
lesion in 
Right 
parieto 
occipital 
region-
K/C of 
lung 
carcinoma 
MGBST 
Secondary 
papillary 
adeno 
carcinomatou
s deposits 
  - 
++
+ 
- - 
++
+ 
++
+ 
      
34 28/10 
51
Y 
F 
Altered 
sensorium, 
head ache 
Left o 
fronto 
parietal 
hyper 
dense 
SOL with 
mass 
effect 
MGWS
T 
Secondary 
papillary 
adeno 
carcinomatou
s deposits 
  - 
++
+ 
- - 
++
+ 
++
+ 
      
35 48/10 
67
Y 
F 
head ache, 
vomiting 
Right 
parietal 
SOL-K/C 
of FGT 
malignanc
y- Ovary 
MGBST 
Secondary 
papillary 
adeno 
carcinomatou
s deposits 
  - 
++
+ 
- - 
++
+ 
++
+ 
      
36 411/10 
27
Y 
F 
Giddiness, 
head ache  
Right 
cerebellar 
SOL with 
contrast 
enhancem
ent 
MGWS
T 
Carcinoma 
thyroid 
  - 
++
++ 
- - 
++
+ 
++
+ 
+++     
37 505/10 
50
Y 
F 
head ache, 
vomiting 
Right 
frontal 
SOL-K/C 
of lung 
carcinoma 
MGBST 
Secondary 
papillary 
adeno 
carcinomatou
s deposits 
  - 
++
+ 
- - 
++
+ 
        
38 487/11 
50
Y 
F 
head ache, 
vomiting 
Right 
frontal 
SOL with 
ring 
enhancem
ent- K/C 
of 
Carcinom
a breast 
MGWS
T 
Secondary 
papillary 
adeno 
carcinomatou
s deposits 
  - 
++
+ 
- - 
++
+ 
++
+ 
  - - 
39 492/11 
62
Y 
F 
Giddiness, 
head ache  
cerebellar 
SOL 
MGBST 
Secondary 
papillary 
adeno 
carcinomatou
s deposits 
  - 
++
+ 
- - 
++
+ 
++
+ 
      
40 125/07 
22
Y 
M 
Low back 
ache 
L1 intra 
medullary 
SOL 
extending 
up to 
medulla 
GWST  
Myxo 
papillary 
Ependymom
a 
  +++ - - - - -       
41 287/07 
60
Y 
M 
Upper limb 
& lower limb 
weakness 
Intra dural 
extra 
medullary 
SOL L3 
MGWS
T 
Myxo 
papillary 
Ependymom
a 
  +++ - - - - -       
42 82/09 
30
Y 
M 
Right pain 
thigh 
L4-L5 
intra dural 
and 
intramedu
llary SOL 
MGWS
T 
Myxo 
papillary 
Ependymom
a 
  ++ - - - - -       
43 140/09 
18
Y 
M 
Numbness in 
both limb 
D12-L1 
intra dural 
SOL 
MGWS
T 
Myxo 
papillary 
Ependymom
a 
  +++ - - ++ - -       
44 417/11 
56
Y 
F 
Low back 
ache 
Solid & 
cystic 
intra 
medullary 
SOL in 
cauda 
equina 
MGWS
T 
Myxo 
papillary 
Ependymom
a 
  +++ - - - - -       
45 197/08 
34
Y 
M 
weakness of 
upper limb & 
lower limb 
L3-L4 
SOL 
MGWS
T 
Myxo 
papillary 
Ependymom
a 
  +++ - - - - -       
46 606/11 
17
Y 
M 
Low back 
ache 
L1-L2 
intra dural 
SOL 
MGWS
T 
Myxo 
papillary 
Ependymom
a 
  - - - - - -       
47 14/07 
18
Y 
M head ache 
Hyper 
density in 
right 
posterior 
fossa  
MGWS
T 
papillary 
meningioma 
  NA - - NA - -       
48 197/07 
38
Y 
M 
head ache, 
weakness 
Right 
parietal 
convexity 
meningio
ma 
MGWS
T 
papillary 
meningioma 
  + - - +++ - 
++
+ 
      
49 386/07 
21
Y 
M head ache 
Hyper 
dense 
large 
lesion in 
right 
Parieto 
occipital 
region 
MGWS
T 
papillary 
meningioma 
  NA NA NA NA - NA NA 
N
A 
N
A 
50 392/10 
27
Y 
M 
head ache, 
vomiting 
increase 
in signal 
intensity 
of 3*3cm 
right 
frontal 
region 
MGWS
T 
papillary 
meningioma 
  - - - ++ - -       
51 157/11 
53
Y 
M head ache 
Right 
frontal 
SOL with 
surroundi
ng edema 
MGWS
T 
papillary 
meningioma 
  - - - +++ - -       
52 162/07 
4/1
2Y 
F - 
Choroid 
plexus 
SOL( 
lateral 
ventricle) 
MGBST 
choroid 
plexus 
papilloma 
  - 
++
+ 
++
+ 
- - -       
53 115/09 1Y F 
development
al delay 
well 
circumscri
bed hyper 
dense 
lesion 
noted in 
lateral 
ventricle 
MGBST 
choroid 
plexus 
papilloma 
  - ++ 
++
++ 
- - -       
54 479/09 
6/1
2Y 
F 
Hydrocephal
us 
Intraventri
cular 
isodense 
irregular 
lesion in 
3rd 
ventricle 
MGBST 
choroid 
plexus 
papilloma 
with focal 
atypia 
  NA NA NA NA - - NA 
N
A 
N
A 
55 517/11 8Y M 
Hydrocephal
us 
Posterior 
3rd 
ventricle 
SOL 
MGBST 
choroid 
plexus 
papilloma 
with focal 
atypia 
  - - 
++
+ 
++ - -       
56 460/07 
15
Y 
M 
Hydrocephal
us 
Right 
lateral 
ventricle 
SOL 
MGWS
T 
Choroid 
plexus 
carcinoma 
  NA NA NA NA - - NA 
N
A 
N
A 
57 363/10 7Y M 
Hydrocephal
us 
Lateral 
ventricle 
SOL 
MGBST 
Choroid 
plexus 
carcinoma 
  - - - - - -       
58 2/08 
36
Y 
F 
head ache, 
blurring of 
vision 
large 
irregular 
shaped 
solid & 
cystic 
SOL in 
Sellar 
region 
MGWS
T 
Papillary 
variant of 
craniopharyn
gioma 
  -   - - - -       
59 172/08 
20
Y 
M 
seizure, head 
ache 
Hyper 
dense 
lesion in 
Sellar 
region 
MGWS
T 
Papillary 
variant of 
craniopharyn
gioma 
  -   - - - -       
60 335/10 
18
Y 
M 
head ache, 
blurring of 
vision 
Sellar 
SOL with 
contrast 
enhancem
ent 
MGBST 
and 
hemorrh
agic area 
Papillary 
ependymoma 
  NA NA NA NA - - NA 
N
A 
N
A 
61 163/11 1Y F 
seizure, head 
ache 
Posterior 
fossa SOL 
MWST 
Ependymobl
astoma 
  ++   ++ ++ - -       
62 340/11 1Y M 
weakness of 
upper limb & 
lower limb 
D2-D7 
intradural 
SOL 
MWST PNET   NA NA NA NA - - NA 
N
A 
N
A 
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SOL- space occupying lesion 
PNET- primitive neuro ectodermal tumour 
MGBST- multiple grey brown soft tissues 
MGWST- multiple grey white soft tissues 
MWST- multiple whitish soft tissues 
+- 1 + positive 
++ - 2+ positive 
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FIG 1: MYXOID (BLUE ARROW) REGION WITH CENTRAL 
BLOOD VESSEL CORE (RED ARROW) SURROUNDED BY EPENDYMAL 
CELLS (BLACK ARROW) 
FIG 2: GFAP CYTOPLASMIC 
POSITIVITY 
 IN EPENDYMAL CELLS 
FIG 3: VIM- CYTOPLASMIC 
POSITIVITY 
 IN EPENDYMAL CELLS 
MYXOPAPILLARY EPENDYMOMA 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
FIG 4: PAPILLARY PATTERN (LOW POWER) (RED 
ARROW) 
FIG 5: CK- CYTOPLASMIC POSITIVITY IN TUMOUR 
CELLS (RED ARROW) 
CHOROID PLEXUS PAPILLOMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
FIG 6: PAPILLARY PATTERN (HIGH POWER- CUBOIDAL 
TO COLUMNAR CELLS) (RED ARROW) 
FIG 7: S-100 CYTOPLASMIC POSITIVITY N TUMOUR 
CELLS 
CHOROID PLEXUS PAPILLOMA 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 8: PAPILLARY PATTERN (BLACK ARROW), SOLID 
SHEET(RED ARROW) 
CHOROID PLEXUS PAPILLOMA WITH ATYPIA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 9: PAPILLARY PATTERN, STRATIFICATION OF 
CELLS, ATYPIA 
FIG 10: PAPILLARY PATTERN WITH FOCAL ATYPIA 
FIG 11: CK- DIFFUSE CYTOPLASMIC 
 POSITIVITY  
FIG 12: S-100- FOCAL CYTOPLASMIC 
 POSITIVITY  
CHOROID PLEXUS PAPILLOMA WITH ATYPIA 
 
 
 
 
 
 
 
 
 
 
 
  
 
FIG 13: PATTERNLESS SHEETS & FOCAL PAPILLARY 
PATTERN  
FIG 14: PATTERNLESS SHEETS & FOCAL PAPILLARY 
PATTERN  
CHOROID PLEXUS CARCINOMA 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
FIG 15: TUMOUR CELLS WITH ATYPIA & MITOSIS 
FIG 16: TUMOUR CELLS NEGATIVE 
 FOR ALL IHC MARKERS 
FIG 17: ADJACENT NORMAL 
CHOROID POSITIVE FOR CK 
CHOROID PLEXUS CARCINOMA 
 
 
 
 
 
 
 
 
 
  
 
 
  
FIG 18 :PAPILLARY PATTERN WITH ELONGATED 
CELLS 
FIG 19: EMA- CYTOPLSMIC POSITIVITY IN TUMOUR 
CELLS 
PAPILLARY MENINGIOMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 20: VIMENTIN – CYTOPLASMIC POSITIVITY IN 
TUMOUR CELLS 
FIG 21: GFAP NEGATIVITY IN TUMOUR CELLS 
PAPILLARY MENINGIOMA 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
FIG 22: CELLS WITH RHABDOID MORPHOLOGY 
FIG 23: DESMIN – CYTOPLASMIC STRONG POSITIVITY 
IN CELLS WITH RHABDOID MORPHOLOGY 
PAPILLARY MENINGIOMA WITH RHABDOID 
DIFFERENTIATION 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 24: VIMENTIN – CYTOPLASMIC STRONG 
POSITIVITY IN CELLS WITH RHABDOID MORPHOLOGY 
FIG 25: GFAP NEGATIVE IN TUMOUR CELLS 
PAPILLARY MENINGIOMA WITH RHABDOID 
DIFFERENTIATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
FIG 26: CENTRAL BLOOD VESSEL CORE (RED) LINED 
BY TUMOUR CELLS (PAPILLARY PATTERN)(BLACK) 
FIG 27: VIMENTIN POSITIVITY IN 
CENTRAL BLOOD VESSEL CORE (RED) 
FIG 28: ALL OTHER 
 MARKERS- NEGATIVE 
PAPILLARY VARIANT OF CRANIOPHARYNGIOMA 
 
 
 
 
 
 
  
 
 
 
  
 
  
FIG 29: DENSE CELLULARITY WITH THIN WALLED 
BLOOD VESSEL 
FIG 30 & 31: GFAP & S-100 POSITIVITY IN EPENDYMOBLASTOMATOUS 
ROSETTES (YELLOW) 
EPENDYMOBLASTOMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 32: PAPILLARY PATTERN, HOBNAIL PATTERN OF 
CELLS, HYPERCHROMATIC NUCLEI 
FIG 33: CK- CYTOPLASMIC STRONG POSITIVITY IN 
TUMOUR CELLS  
METASTATIC DEPOSITS FROM LUNG CARCINOMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 34: HOBNAIL PATTERN OF CELLS (RED) 
HYPERCHROMATIC NUCLEI 
FIG 35: CEA- CYTOPLASMIC & MEMBRANOUS 
POSITIVITY IN TUMOUR CELLS 
METASTATIC DEPOSITS FROM LUNG CARCINOMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 36: PAPILLARY PATTERN (RED) WITH 
HYPERCHROMATIC NUCLEI 
FIG 37: CK- STRONG CYTOPLASMIC & MEMBRANOUS 
POSITIVITY 
METASTATIC PAPILLARY ADENO CARCINOMA DEPOSITS 
FROM UNKNOWN PRIMARY 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
FIG 38: PAPILLARY PATTERN (RED) WITH 
HYPERCHROMATIC PLEOMOPHIC NUCLEI 
FIG 39: CEA- STRONG CYTOPLASMIC & MEMBRANOUS 
POSITIVITY IN TUMOUR CELLS 
METASTATIC PAPILLARY ADENO CARCINOMA DEPOSITS 
FROM UNKNOWN PRIMARY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 40: PAPILLARY CARCINOMA THYROID 
METASTASIS 
FIG 41: THYROGLOBULIN POSITIVITY IN COLLOID 
METASTATIC DEPOSTS FROM THYROID CARCINOMA 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
FIG 42: PAPILLARY PATTERN (RED), STRATIFICATION 
OF NUCLEI, HYPERCHROMATIC NUCLEI 
FIG 43: CK- CYTOPLASMIC POSITIVITY IN TUMOUR 
CELLS 
METASTATIC DEPOSTS FROM OVARIAN CARCINOMA 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
FIG 44: PAPILLARY PATTERN (RED), STRATIFICATION 
OF NUCLEI, HYPERCHROMATIC NUCLEI 
FIG 45: CEA – APICAL CYTOPLASMIC POSITIVITY IN 
TUMOUR CELLS 
METASTATIC DEPOSTS FROM OVARIAN CARCINOMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 46: PAPILLARY PATTERN (RED), STRATIFICATION 
OF NUCLEI, HYPERCHROMATIC NUCLEI 
METASTATIC PAPILLARY ADENO CARCINOMA DEPOSITS 
FROM UNKNOWN PRIMARY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 FIG 47: CK- STRONG CYTOPLASMIC POSITIVITY IN 
TUMOUR CELLS 
FIG 48: CEA- STRONG CYTOPLASMIC & MEMBRANOUS 
POSITIVITY IN TUMOUR CELLS 
FIG 49: GFAP –POSITIVITY IN NORMAL ASTROCYTES 
METASTATIC PAPILLARY ADENO CARCINOMA DEPOSITS 
FROM UNKNOWN PRIMARY 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
ABSTRACT 
TITLE: INCIDENCE OF PAPILLARY NEOPLASMS OF NERVOUS 
SYSTEM IN A TERTIARY CARE HOSPITAL. ROLE OF 
IMMUNOHISTOCHEMISTRY IN THEIR DIFFERENTIAL 
DIAGNOSIS AND CLASSIFICATION 
 
INTRODUCTION: 
 Nervous system neoplasms are common neoplasm affecting both adults 
and children. Incidence, prevalence and survival rates are important to 
know the burden of disease among different populations. Often the 
histological appearance alone cannot conclude the diagnosis. In difficult 
cases use of immunohistochemistry aid in differentiating metastasis from 
primary tumour, histological sub typing and grading. In this study we 
analysed the data from our tertiary care hospital to find the epidemiology 
of papillary neoplasms of nervous system, histopathology, and employed 
immunohistochemistry to differentiate each tumour. 
AIMS AND OBJECTIVES: 
1. To study the incidence of papillary neoplasms of nervous system. 
2. To study the immunohistochemical expression in primary nervous system 
tumours. 
RESULTS: 
 In a study period of 5 years, 62 cases of nervous system tumours with 
papillary pattern were subjected to histological and Immunohistochemical 
analysis to find out the usefulness of IHC in their diagnosis and 
differential diagnosis. The findings were correlated with WHO grading 
and analysis. 
 Metastatic tumours with papillary pattern constituted 62.90% and this 
formed the most common tumours of nervous system. The peak age 
group was between 51 to 60 years with relative percentage of 20.97%. 
CONCLUSION: 
 The incidence of papillary neoplasms of nervous system in this study was 
2.66%. 
 Metastatic deposits with papillary pattern constituted a higher percentage 
and older age group has higher incidence similar to western population. 
 Lung carcinoma producing brain metastasis constituted higher incidence 
similar to western population. 
 In younger age group most of the papillary tumours were choroid plexus 
tumours. 
 
 
 
 
 
